Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT01252953 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification

Study acronym: REVEAL
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Publications: details revised at 1 of 8 entriesv16
  2. Publications: details revised at 1 of 8 entriesv15
  3. Study description shortened, about 7 wordsv14
  4. Study description expanded, about 52 words
    • Publications: 7 to 8
    v13
  5. Study completion date: Apr 2019 to Jan 31, 2037
    • Publications: 6 to 7
    v12
Show 10 earlier versionsHide 10 earlier versions
  1. Re-verified, no change to tracked fieldsv11
  2. Results first posted: May 4, 2018v10 Show 4 more changesShow less
    • Primary endpoint revised
    • Enrollment target: 30624 to 30449
    • Interventions: anacetrapib (Drug), placebo anacetrapib (Drug) to Anacetrapib (Drug), Placebo anacetrapib (Drug)
    • Secondary endpoints expanded, about 21 words
  3. Primary completion date changed from estimate of Jan 2017 to Jan 31, 2017
    • Study completion date: Jan 2017 to Apr 2019
    • Study description expanded, about 29 words
    v9
  4. 2 versions Re-verified since May 29, 2015, no change to tracked fieldsv7-v8
  5. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 30000 to confirmed 30624
    • Site details revised
    v6
  6. Re-verified, no change to tracked fieldsv5
  7. Study description expanded, about 22 wordsv4
  8. Eligibility criteria expanded, about 1 wordv3
  9. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Apr 2011 to Jun 2011
    • Study sites: 0 to 1
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification (REVEAL) trial aims to determine whether lipid modification with anacetrapib 100mg daily reduces the risk of coronary death, myocardial infarction (MI) or coronary revascularization (collectively known as major coronary events) in patients with circulatory problems who have their Low-density Lipoprotein (LDL) cholesterol level treated with a statin.
Trial Details
NCT Number NCT01252953
Lead Sponsor University of Oxford
Collaborators: Merck Sharp & Dohme LLC
Conditions
(from sponsor)		 Atherosclerotic Cardiovascular Disease
Related terms Atherosclerosis, Inhibition, Psychological, Vascular Diseases
Enrollment 30,449 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov